COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS ACLIDINIUM/FORMOTEROL (ACL/ FOR) IN PATIENTS WITH COPD IN THE UNITED KINGDOM

被引：0
|
作者：
Shah, D. [1 ]
Martin, A. [2 ]
Kendall, R. [3 ]
Noorduyn, S. G. [4 ]
Dasari, P. [5 ]
Risebrough, N. [6 ]
Ismaila, A. [7 ]
机构：
[1] ICON plc, Jersey City, NJ USA
[2] GSK, Brentford, England
[3] ICON Plc, Vancouver, BC, Canada
[4] GSK, Value Evidence & Outcomes, Mississauga, ON, Canada
[5] ICON Plc, Houston, TX USA
[6] ICON Plc, Toronto, ON, Canada
[7] GSK, Value Evidence & Outcomes, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE708
引用
收藏
页码：S190 / S191
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF UMECLIDINIUM BROMIDE COMPARED TO TIOTROPIUM BROMIDE FOR SYMPTOMATIC PATIENTS WITH COPD IN THE UK
    Ismaila, A.
    Roberts, G.
    Punekar, Y. S.
    O'Leary, M.
    VALUE IN HEALTH, 2014, 17 (07) : A595 - A595
  • [42] IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/SALMETEROL (FP/SAL), AND BUDESONIDE/FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS
    Slade, David
    Ray, Riju
    Moretz, Chad
    Germain, Guillaume
    Laliberte, Francois
    Shen, Qin
    Duh, Mei Sheng
    MacKnight, Sean
    Hahn, Beth
    CHEST, 2020, 158 (04) : 1718A - 1719A
  • [43] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [44] Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Baptist, Alan P.
    Germain, Guillaume
    Klimek, Jacob
    Laliberte, Francois
    Schell, Robert C.
    Forero-Schwanhaeuser, Sergio
    Moore, Alison
    Noorduyn, Stephen G.
    Paczkowski, Rosirene
    ADVANCES IN THERAPY, 2025, 42 (02) : 1061 - 1074
  • [45] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE VERSUS DUAL THERAPIES IN MODERATE-TO-VERY SEVERE COPD: UNITED KINGDOM ANALYSIS USING THE ETHOS STUDY
    de Nigris, E.
    Treharne, C.
    Brighton, N.
    Holmgren, U.
    Jenkins, M.
    Walker, A.
    Haughney, J.
    VALUE IN HEALTH, 2022, 25 (01) : S46 - S46
  • [46] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE VERSUS DUAL THERAPIES IN MODERATE-TO-VERY SEVERE COPD IN THE UNITED KINGDOM: ANALYSIS BASED ON THE KRONOS STUDY
    de Nigris, E.
    Holmgren, U.
    Treharne, C.
    Brighton, N.
    Walker, A.
    Haughney, J.
    THORAX, 2021, 76 : A66 - A66
  • [47] Cost-effectiveness of adding budesonide/formoterol to tiotropium in severe COPD patients in four Nordic countries
    Nielsen, Rune
    Kankaanranta, Hannu
    Bjermer, Leif
    Lange, Peter
    Arnetorp, Sofie
    Hedegaard, Morten
    Stenling, Anna
    Mittmann, Nicole
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [48] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK
    Yogesh Suresh Punekar
    Graeme Roberts
    Afisi Ismaila
    Martin O’Leary
    Cost Effectiveness and Resource Allocation, 13
  • [49] Cost-Effectiveness of Risedronate versus Ibandronate at One Year: The Case of the United Kingdom.
    Farquhar, D.
    Pasquale, M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S212 - S212
  • [50] Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
    Amdahl, Jordan
    Diaz, Jose
    Sharma, Arati
    Park, Jinhee
    Chandiwana, David
    Delea, Thomas E.
    PLOS ONE, 2017, 12 (06):
12345